Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has announced plans to initiate a Health Canada-authorized Phase 3 clinical trial in 2027 evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD). The trial is intended to enroll up to 100 participants across multiple Canadian sites, focusing on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters, and healthcare workers. Participants will receive Optimi's synthetic MDMA HCl during two supervised sessions combining MDMA and psychotherapy, with the primary efficacy endpoint measuring changes in PTSD severity using the Clinician-Administered PTSD Scale.
The planned Phase 3 trial follows Optimi's recently announced Phase 2 trial of natural psilocybin for major depressive disorder and is part of the company's goal of pursuing registration for both products. Optimi noted that the safety and efficacy of MDMA-assisted therapy for PTSD remain under investigation and none of its MDMA drug products have received market authorization from Health Canada. The company said clinics in Australia have been prescribing MDMA manufactured by Optimi since October 2024. To view the full press release, visit https://ibn.fm/tr50L.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, visit https://www.optimi.net/.
This announcement matters because it represents a significant step toward regulatory approval of MDMA-assisted therapy in Canada, potentially offering a new treatment avenue for PTSD, a condition that disproportionately affects veterans and frontline workers. If successful, the trial could lead to market authorization, expanding access to psychedelic-assisted therapies and setting a precedent for other countries. For the industry, it underscores the growing acceptance of psychedelics in mainstream medicine and highlights the economic potential for companies like Optimi Health that are positioned to supply regulated psychedelic products. As the mental health crisis continues to impact millions, this trial could pave the way for innovative, evidence-based treatments that address unmet needs.
